PMID- 26379437
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150918
LR  - 20201001
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 11
DP  - 2015
TI  - Platelet activating factors are associated with depressive symptoms in coronary 
      artery disease patients: a hypothesis-generating study.
PG  - 2309-14
LID - 10.2147/NDT.S87111 [doi]
AB  - INTRODUCTION: Depression is a frequent complication of coronary artery disease 
      (CAD) with an unknown etiology. Platelet activating factor (PAF) lipids, which 
      are associated with CAD, have recently been linked with novel proposed 
      etiopathological mechanisms for depression such as inflammation, 
      oxidative/nitrosative stress, and vascular endothelial dysfunction. METHODS AND 
      RESULTS: This hypothesis-generating study investigated the relationships between 
      various PAF species and depressive symptoms in 26 CAD patients (age: 60.6+/-9.2 
      years, 69% male, mean Hamilton Depression Rating Scale [HAM-D] score: 11.8+/-5.2, 
      HAM-D range: 3-20). Plasma PAF analyses were performed using high performance 
      liquid chromatography electrospray ionization mass spectrometry in precursor ion 
      scan. Significant associations between depressive symptom severity (HAM-D score) 
      and a greater plasma abundance of the PAFs phosphocholine (PC) PC(O-12:0/2:0) 
      (r=0.49, P=0.01), PC(O-14:1/2:0) (r=0.43, P=0.03), PC(O-17:3/2:0) (r=0.44, 
      P=0.04), and PC(O-18:3/2:0) (r=0.50, P=0.01) were observed. Associations between 
      those PAFs and HAM-D score persisted after adjusting for age and sex. CONCLUSION: 
      These preliminary findings support the exploration of the PAF lipidome for 
      depressive symptom biomarkers in CAD patients. Patients were recruited as part of 
      the following clinical trial: NCT00981383.
FAU - Mazereeuw, Graham
AU  - Mazereeuw G
AD  - Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Sunnybrook Health 
      Sciences Centre, Toronto, ON, Canada ; Department of Pharmacology and Toxicology, 
      University of Toronto, Toronto, ON, Canada ; CIHR Training Program in 
      Neurodegenerative Lipidomics, Department of Biochemistry, Microbiology, and 
      Immunology, University of Ottawa, Ottawa, ON, Canada.
FAU - Herrmann, Nathan
AU  - Herrmann N
AD  - Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Sunnybrook Health 
      Sciences Centre, Toronto, ON, Canada ; Department of Psychiatry, University of 
      Toronto, Toronto, ON, Canada.
FAU - Xu, Hongbin
AU  - Xu H
AD  - Ottawa Institute of Systems Biology and Neural Regeneration Laboratory, 
      Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, 
      Ottawa, ON, Canada ; CIHR Training Program in Neurodegenerative Lipidomics, 
      Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, 
      Ottawa, ON, Canada.
FAU - Blanchard, Alexandre P
AU  - Blanchard AP
AD  - Ottawa Institute of Systems Biology and Neural Regeneration Laboratory, 
      Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, 
      Ottawa, ON, Canada ; CIHR Training Program in Neurodegenerative Lipidomics, 
      Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, 
      Ottawa, ON, Canada.
FAU - Figeys, Daniel
AU  - Figeys D
AD  - Ottawa Institute of Systems Biology and Neural Regeneration Laboratory, 
      Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, 
      Ottawa, ON, Canada ; CIHR Training Program in Neurodegenerative Lipidomics, 
      Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, 
      Ottawa, ON, Canada.
FAU - Oh, Paul I
AU  - Oh PI
AD  - UHN Toronto Rehabilitation Institute, Toronto, ON, Canada.
FAU - Bennett, Steffany Al
AU  - Bennett SA
AD  - Ottawa Institute of Systems Biology and Neural Regeneration Laboratory, 
      Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, 
      Ottawa, ON, Canada ; CIHR Training Program in Neurodegenerative Lipidomics, 
      Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, 
      Ottawa, ON, Canada.
FAU - Lanctot, Krista L
AU  - Lanctot KL
AD  - Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Sunnybrook Health 
      Sciences Centre, Toronto, ON, Canada ; Department of Pharmacology and Toxicology, 
      University of Toronto, Toronto, ON, Canada ; CIHR Training Program in 
      Neurodegenerative Lipidomics, Department of Biochemistry, Microbiology, and 
      Immunology, University of Ottawa, Ottawa, ON, Canada ; Department of Psychiatry, 
      University of Toronto, Toronto, ON, Canada ; UHN Toronto Rehabilitation 
      Institute, Toronto, ON, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT00981383
PT  - Journal Article
DEP - 20150904
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC4567245
OTO - NOTNLM
OT  - biomarker
OT  - cardiovascular
OT  - depression
OT  - inflammation
OT  - lipidomics
OT  - oxidative stress
OT  - vascular depression
EDAT- 2015/09/18 06:00
MHDA- 2015/09/18 06:01
PMCR- 2015/09/04
CRDT- 2015/09/18 06:00
PHST- 2015/09/18 06:00 [entrez]
PHST- 2015/09/18 06:00 [pubmed]
PHST- 2015/09/18 06:01 [medline]
PHST- 2015/09/04 00:00 [pmc-release]
AID - ndt-11-2309 [pii]
AID - 10.2147/NDT.S87111 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2015 Sep 4;11:2309-14. doi: 10.2147/NDT.S87111. 
      eCollection 2015.